ICON TO ACQUIRE PRA HEALTH SCIENCES, CREATING A WORLD LEADER IN HEALTHCARE INTELLIGENCE AND CLINICAL RESEARCH

DUBLIN–( BUSINESS WIRE )– ICON plc , (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and government and public health organisations, today announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. The consideration represents an approximately 30% premium to PRA’s closing price as of February 23 rd , 2021.

The transaction brings together two high-quality, innovative and growing organisations with similar cultures and a shared focus on high quality and efficient clinical trial execution from Phase 1 to post-approval studies.

Read the full article at: https://www.businesswire.com/news/home/20210224005484/en/ICON-to-Acquire-PRA-Health-Sciences-Creating-a-World-Leader-in-Healthcare-Intelligence-and-Clinical-Research#.YDZJEgExMLE.linkedin

Won’t you get hip to this kindly tip, get your kicks on Route 505(b)(2). What is that?Route 505(b)(2) vs. 505(j)Altasciences Acquires WCCT Global“ This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early phase drug development solution to address the ever-changing outsourcing challenges of biopAn Overview of GDUFAThe Office of Generic Drugs (OGD) reports directly to the Director of the Center for Drug Evaluation and Research (CDER). The OGD’s mission is to ensure safe, effective, and affordable medicines for the American public.Catawba Research Concludes Another Rosacea Clinical TrialCatawba Research is pleased to announce another achievement for a recently completed rosacea clinical trial. In this trial, Catawba enrolled more than 1000 rosacea subjects in 22 weeks from 33 sites .Catawba Research Achieves Acne First-to-FileThe team at Catawba Research has recently completed a first-to-file submission for acne clinical trial . In this study, Catawba enrolled a staggering 1125 acne vulgaris subjects in 8 weeks from 12 sites .Catawba Research Adds Tinea Pedis Video to Training LibraryTo learn more about our training program or see some our videos, contact us !